267 related articles for article (PubMed ID: 15247129)
1. Lysophospholipids are potential biomarkers of ovarian cancer.
Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis.
Murph M; Tanaka T; Pang J; Felix E; Liu S; Trost R; Godwin AK; Newman R; Mills G
Methods Enzymol; 2007; 433():1-25. PubMed ID: 17954226
[TBL] [Abstract][Full Text] [Related]
4. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells.
Schwartz BM; Hong G; Morrison BH; Wu W; Baudhuin LM; Xiao YJ; Mok SC; Xu Y
Gynecol Oncol; 2001 May; 81(2):291-300. PubMed ID: 11330965
[TBL] [Abstract][Full Text] [Related]
5. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
6. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer.
Zhao Z; Xiao Y; Elson P; Tan H; Plummer SJ; Berk M; Aung PP; Lavery IC; Achkar JP; Li L; Casey G; Xu Y
J Clin Oncol; 2007 Jul; 25(19):2696-701. PubMed ID: 17602074
[TBL] [Abstract][Full Text] [Related]
7. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids.
Xiao YJ; Schwartz B; Washington M; Kennedy A; Webster K; Belinson J; Xu Y
Anal Biochem; 2001 Mar; 290(2):302-13. PubMed ID: 11237333
[TBL] [Abstract][Full Text] [Related]
8. The role and clinical applications of bioactive lysolipids in ovarian cancer.
Xu Y; Xiao YJ; Baudhuin LM; Schwartz BM
J Soc Gynecol Investig; 2001; 8(1):1-13. PubMed ID: 11223350
[TBL] [Abstract][Full Text] [Related]
9. S1P regulation of ovarian carcinoma invasiveness.
Smicun Y; Reierstad S; Wang FQ; Lee C; Fishman DA
Gynecol Oncol; 2006 Dec; 103(3):952-9. PubMed ID: 16956652
[TBL] [Abstract][Full Text] [Related]
10. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses.
Xiao Y; Chen Y; Kennedy AW; Belinson J; Xu Y
Ann N Y Acad Sci; 2000 Apr; 905():242-59. PubMed ID: 10818458
[TBL] [Abstract][Full Text] [Related]
12. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry.
Baker DL; Desiderio DM; Miller DD; Tolley B; Tigyi GJ
Anal Biochem; 2001 May; 292(2):287-95. PubMed ID: 11355863
[TBL] [Abstract][Full Text] [Related]
13. Unfolding the pathophysiological role of bioactive lysophospholipids.
Xu Y; Xiao YJ; Zhu K; Baudhuin LM; Lu J; Hong G; Kim KS; Cristina KL; Song L; S Williams F; Elson P; Markman M; Belinson J
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Mar; 3(1):23-32. PubMed ID: 12570723
[TBL] [Abstract][Full Text] [Related]
14. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
Wang Q; Zhang W; Li DR; Li L
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1012-6. PubMed ID: 18754431
[TBL] [Abstract][Full Text] [Related]
15. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
16. Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer.
Woong-Shick A; Sung-Pil P; Su-Mi B; Joon-Mo L; Sung-Eun N; Gye-Hyun N; Young-Lae C; Ho-Sun C; Heung-Jae J; Chong-Kook K; Young-Wan K; Byoung-Don H; Hyun-Sun J
Cancer Sci; 2005 Mar; 96(3):197-201. PubMed ID: 15771624
[TBL] [Abstract][Full Text] [Related]
17. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
18. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
19. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
[TBL] [Abstract][Full Text] [Related]
20. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
Wang P; Wu X; Chen W; Liu J; Wang X
Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
